UNSPSC 51161708: Desoxyribonuclease or dornase alfa

This classification denotes an enzyme replacement preparation with the molecular formula C1321H1995N339O396S9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 953A26OA1Y, more generally known as dornase alfa. European Medicines Agency schedules dornase alfa in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06373MIG. The term DORNASE ALFA is an International Non-Proprietary Name or INN. Most nations schedule dornase alfa under HS 35079090 and SITC 51691.

As of Q4 2014, DORNASE ALFA remains the US FDA Preferred Term for this commodity. Dornase alfa bears US NLM identifiers UMLS ID C1135662 and NCI Concept Code C81664. SMILES: NONE.

UNSPSC 51161708 Desoxyribonuclease or dornase alfa is a Commodity code that covers pharmaceutical agents used in intravenous and parenteral therapies. State and local procurement under this code focuses on sourcing parenteral products and services — including parenteral nutrition solutions (TPN and PPN), intravenous solutions, and related pharmaceutical agents such as controlled substances — for delivery to correctional health systems, hospitals, and other state healthcare facilities. The issuing bodies are primarily state departments of corrections and state health agencies responsible for providing medically necessary healthcare to incarcerated populations or institutionalized patients. Bidders must hold documented experience in preparing and delivering IV and parenteral nutrition solutions, monitoring patient laboratory results, and adjusting formulations to clinical specifications; meet state business licensure and background-clearance requirements; and maintain comprehensive insurance including Commercial General Liability, Professional Liability, Business Automobile Liability, and Cyber Liability coverage.

The most recent activity appears concentrated in Washington State. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026 for parenteral products, services, and equipment to supply eight correctional facilities across West, Central, and East regions, with responses due October 7, 2026 at 4:00 PM PST and a pre-bid conference on September 23, 2026. The contract contemplates multiple awards (up to three bidders per region) for an initial term running November 26, 2026 through June 30, 2030, with fixed pricing required through the two-year mark. DOC encourages participation from small businesses (25% aspirational goal), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%), all certified through appropriate state agencies. Delivery windows are stringent — parenteral nutrition bags must be supplied within 24 hours of order with same-day delivery by 5:00 PM for subsequent orders; other parenteral products must arrive within 8 hours for the initial 24-hour supply, with DOC declining to pay for deliveries exceeding 24 hours after order placement.